Grant Award Details

Next generation affinity-tuned CAR for prostate cancer
Grant Number: 
TRAN1-13370
Project Objective: 
  • To conduct a well-prepared pre-IND meeting with FDA for a Next generation affinity-tuned CAR for prostate cancer
Investigator: 
Type: 
PI
Disease Focus: 
Cancer
Prostate Cancer
Solid Tumors
Award Value: 
$5,805,144
Status: 
Active

Grant Application Details

Application Title: 
  • Next generation affinity-tuned CAR for prostate cancer
Public Abstract: 

Translational Candidate

A next generation cell therapy product that targets prostate cancer cells

Area of Impact

Prostate cancer

Mechanism of Action

The therapeutic candidate when expressed on the surface of immune cells allow them to binds to a protein that is overexpressed on the prostate cancer cells and kills them.

Unmet Medical Need

Prostate cancer is the fourth most common cancer globally and the second leading cause of cancer death among men in the United States, with a 60% occurrence rate in men over the age of 65. Approximately 61,860 patients are expected to die from prostate cancer in California in the year 2021.

Project Objective

pre-IND meeting

Major Proposed Activities

  • Generate GMP compatible lentiviral vector encoding the therapeutic candidate
  • Process development and scale up for cGMP manufacturing of the therapeutic candidate
  • Rodent studies to determine the efficacy and safety of cGMP manufactured therapeutic candidate
Statement of Benefit to California: 

Californians will benefit in several significant ways. Approximately 61,860 patients die from prostate cancer in California every year. If the therapeutic is successful, it will extend the long-term survival rates for Californians with prostate cancer. The proposed studies will have an added economic benefit for California by creating skilled jobs and new companies. The current therapeutic would also reduce hospital cost through improved efficacy and safety.